Paracrine Induction of Epithelial-Mesenchymal Transition Between Colorectal Cancer Cells and Its Suppression by a P53/miR-192/215/NID1 Axis

Overview

Journal Cell Mol Gastroenterol Hepatol

Specialty Gastroenterology

Date 2019 Mar 5

PMID 30831320

Citations 18

Authors

Matjaz Rokavec

Nassim Bouznad

Heiko Hermeking

Affiliations

Soon will be listed here.

Abstract

Background & Aims: Intratumor heterogeneity is a common feature of colorectal cancer (CRC). Here, we analyzed whether mesenchymal-like CRC cells promote the progression of epithelial-like CRC cells via paracrine mechanisms.

Methods: Six CRC cell lines that show an epithelial phenotype were treated with conditioned media (CM) from CRC cell lines that show a mesenchymal phenotype, and effects on epithelial-mesenchymal transition (EMT), migration, invasion, and chemoresistance were determined. Secreted factors potentially mediating these effects were identified by using cytokine arrays. Associations of these factors with tumor progression and patient survival were determined.

Results: CM obtained from mesenchymal-like CRC cells induced EMT associated with increased migration, invasion, and chemoresistance in epithelial-like CRC cell lines. Notably, activation of p53 in mesenchymal-like CRC cells prevented these effects of CM. Increased concentrations of several cytokines were identified in CM from mesenchymal-like CRC cell lines and a subset of these cytokines showed repression by p53. The down-regulation of nidogen-1 (NID1) was particularly significant and was owing to p53-mediated induction of microRNA-192 and microRNA-215, which directly target the NID1 messenger RNA. NID1 was found to be required and sufficient for inducing EMT, invasion, and migration in epithelial-like CRC cells. In primary CRCs, increased NID1 expression was associated with p53 mutation and microRNA-192/215 down-regulation. Importantly, increased NID1 expression in CRCs correlated with enhanced tumor progression and poor patient survival.

Conclusions: Taken together, our results show that CRC cells promote tumor progression via secreting NID1, which induces EMT in neighboring tumor cells. Importantly, the interference of p53 with this paracrine signaling between tumor cells may critically contribute to tumor suppression.

Citing Articles

Molecular mechanisms of miR-192 in cancer: a biomarker and therapeutic target.

Yang Y, Razak S, Ismail I, Ma Y, Yunus M Cancer Cell Int. 2025; 25(1):94.

PMID: 40087755 DOI: 10.1186/s12935-025-03666-5.

Exploration and validation of a novel reactive oxygen species-related signature for predicting the prognosis and chemotherapy response of patients with bladder cancer.

Li Y, Zhang L, Xu G, Chen J, Zhao K, Li M Front Immunol. 2025; 15:1493528.

PMID: 39749345 PMC: 11693660. DOI: 10.3389/fimmu.2024.1493528.

NID1 promotes laryngeal cancer stemness via activating WNT pathway.

Liu W, Wu J, Lai Y, Zhang S, Yang A, Li Y Biol Direct. 2024; 19(1):115.

PMID: 39538332 PMC: 11558908. DOI: 10.1186/s13062-024-00548-0.

ECM Proteins Nidogen-1 and Decorin Restore Functionality of Human Islets of Langerhans upon Hypoxic Conditions.

Jeyagaran A, Urbanczyk M, Carvajal-Berrio D, Baldissera T, Kaiser P, Kuhlburger L Adv Healthc Mater. 2024; 14(2):e2403017.

PMID: 39511898 PMC: 11730087. DOI: 10.1002/adhm.202403017.

Identification of HSPG2 as a bladder pro-tumor protein through NID1/AKT signaling.

Li C, Luo P, Guo F, Jia X, Shen M, Zhang T Cancer Cell Int. 2024; 24(1):345.

PMID: 39438949 PMC: 11515648. DOI: 10.1186/s12935-024-03527-7.

References

Muller P, Vousden K, Norman J . p53 and its mutants in tumor cell migration and invasion. J Cell Biol. 2011; 192(2):209-18. PMC: 3172183. DOI: 10.1083/jcb.201009059. View

Almendro V, Marusyk A, Polyak K . Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol. 2012; 8:277-302. DOI: 10.1146/annurev-pathol-020712-163923. View

Budczies J, Klauschen F, Sinn B, Gyorffy B, Schmitt W, Darb-Esfahani S . Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012; 7(12):e51862. PMC: 3522617. DOI: 10.1371/journal.pone.0051862. View

Powell E, Piwnica-Worms D, Piwnica-Worms H . Contribution of p53 to metastasis. Cancer Discov. 2014; 4(4):405-14. PMC: 4063123. DOI: 10.1158/2159-8290.CD-13-0136. View

Hahn S, Jackstadt R, Siemens H, Hunten S, Hermeking H . SNAIL and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial-mesenchymal transition. EMBO J. 2013; 32(23):3079-95. PMC: 3844956. DOI: 10.1038/emboj.2013.236. View

Chen J, Yuan W, Wu L, Tang Q, Xia Q, Ji J . PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1/Twist1 pathway. Oncotarget. 2016; 8(6):9961-9973. PMC: 5354784. DOI: 10.18632/oncotarget.14283. View

Sottoriva A, Kang H, Ma Z, Graham T, Salomon M, Zhao J . A Big Bang model of human colorectal tumor growth. Nat Genet. 2015; 47(3):209-16. PMC: 4575589. DOI: 10.1038/ng.3214. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

Joung J, Oh B, Hong H, Al-Khalidi H, Al-Alem F, Lee H . Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer. Clin Cancer Res. 2017; 23(23):7209-7216. DOI: 10.1158/1078-0432.CCR-17-0306. View

10.

Hunten S, Siemens H, Kaller M, Hermeking H . The p53/microRNA network in cancer: experimental and bioinformatics approaches. Adv Exp Med Biol. 2013; 774:77-101. DOI: 10.1007/978-94-007-5590-1_5. View

11.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

12.

Wu Q, Hou X, Xia J, Qian X, Miele L, Sarkar F . Emerging roles of PDGF-D in EMT progression during tumorigenesis. Cancer Treat Rev. 2012; 39(6):640-6. PMC: 3619006. DOI: 10.1016/j.ctrv.2012.11.006. View

13.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

14.

Tsai J, Yang J . Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013; 27(20):2192-206. PMC: 3814640. DOI: 10.1101/gad.225334.113. View

15.

Shin S, Dimitri C, Yoon S, Dowdle W, Blenis J . ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell. 2010; 38(1):114-27. PMC: 2854677. DOI: 10.1016/j.molcel.2010.02.020. View

16.

Punt C, Koopman M, Vermeulen L . From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2016; 14(4):235-246. DOI: 10.1038/nrclinonc.2016.171. View

17.

Hermeking H . MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer. 2012; 12(9):613-26. DOI: 10.1038/nrc3318. View

18.

Ekblom P, Ekblom M, Fecker L, Klein G, Zhang H, Kadoya Y . Role of mesenchymal nidogen for epithelial morphogenesis in vitro. Development. 1994; 120(7):2003-14. DOI: 10.1242/dev.120.7.2003. View

19.

Wang R, Li Y, Hou Y, Yang Q, Chen S, Wang X . The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells. Oncotarget. 2015; 6(9):7000-10. PMC: 4466665. DOI: 10.18632/oncotarget.3193. View

20.

Saxena M, Stephens M, Pathak H, Rangarajan A . Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011; 2:e179. PMC: 3199722. DOI: 10.1038/cddis.2011.61. View